Last reviewed · How we verify

Bimekizumab regimen 2 iv

UCB Biopharma SRL · Phase 1 active Small molecule

Bimekizumab regimen 2 iv is a Small molecule drug developed by UCB Biopharma SRL. It is currently in Phase 1 development.

At a glance

Generic nameBimekizumab regimen 2 iv
SponsorUCB Biopharma SRL
ModalitySmall molecule
PhasePhase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Bimekizumab regimen 2 iv

What is Bimekizumab regimen 2 iv?

Bimekizumab regimen 2 iv is a Small molecule drug developed by UCB Biopharma SRL.

Who makes Bimekizumab regimen 2 iv?

Bimekizumab regimen 2 iv is developed by UCB Biopharma SRL (see full UCB Biopharma SRL pipeline at /company/ucb-biopharma-srl).

What development phase is Bimekizumab regimen 2 iv in?

Bimekizumab regimen 2 iv is in Phase 1.

Related